Home / Transcripts / AVITA Medical, Inc. (RCEL) · August 6, 2026

AVITA Medical, Inc. (RCEL) Earnings Call Transcript

August 6, 2026

NASDAQ US Health Care Biotechnology earnings 26 min

Earnings Call Speaker Segments

Ben Atkins executive
#1

Thanks, operator. I'd like to welcome everyone to the earnings call for AVITA Medical's second quarter of 2026. With me today are Cary Vance, our President and Chief Executive Officer, and David O'Toole, our Chief Financial Officer. You can find today's earnings release along with the presentation on our website, www.avitamedical.com, in the investor relations section. Before we get started, I want to note that forward-looking statements are included in this call, as defined under the Private Securities Litigation Reform Act of 1995. Such statements aren't promises or guarantees, and they carry both known and unknown risks and uncertainties that might cause actual results to differ materially from any expectations expressed or implied by those forward-looking statements. For full descriptions of the risk factors, please look at our most recent filings with the SEC. Any forward-looking statements made on this call reflect management's expectations as of today. I'll now hand the call over to Cary.

Cary Vance executive
#2

Good afternoon to everyone in the U.S., and good morning to those of you in Australia. We appreciate you being with us. As today's press release showed, we achieved robust revenue growth during the second quarter, reaching $21.7 million, which represents an 18% increase versus the same period last year and 13% growth over the prior quarter. With AVITA continuing to grow throughout the U.S. and strengthen its footprint across important international markets, these results demonstrate the expanding value of our acute wound care offerings, spearheaded by RECELL and bolstered by Cohealyx and PermeaDerm. Within the U.S., RECELL brought in $18.5 million of revenue in the second quarter, rising roughly 13% from the preceding quarter. That increase stemmed from physician usage after reimbursement for physicians stabilized, along with greater uptake of RECELL GO mini, which keeps broadening its application to smaller wounds. I'll provide additional detail on RECELL afterward in my comments. On the international side, RECELL revenue climbed about 26% from the first quarter. We remain engaged in commercializing RECELL GO after receiving regulatory authorizations across Europe, the U.K., Australia, and New Zealand. As uptake grows, clinicians are starting to discuss their initial clinical findings. In the quarter, the British Burn Association annual meeting showcased the first U.K. clinical experience with RECELL GO, describing successful treatment of 17 patients and emphasizing better operating room workflow. Although international revenue is still a modest portion today, these achievements keep laying the groundwork for long-term growth alongside our substantial U.S. opportunity. Cohealyx produced $1.7 million, which amounts to roughly 16% growth over the prior quarter. We're pleased by the consistent progress as hospitals finish their value analysis committee, or VAC, reviews and start integrating Cohealyx into clinical practice. We continue to keep a robust pipeline of roughly 55 active VAC reviews, with 10 to 15 reviews generally finishing each quarter, which drives a consistent rise in ordering accounts. The interim Cohealyx-I clinical data shared earlier this year reinforces those trends by giving hospitals and surgeons comparative clinical evidence. The study showed considerably faster time to skin graft readiness relative to leading dermal matrices. Later this year, we plan to submit the full six-month follow-up data set for publication, which will offer further evidence of long-term durability. PermeaDerm brought in $600,000 of revenue during the quarter. Commercial adoption is still at an early stage. We're encouraged by the initial response after our recent positioning of PermeaDerm as a wound temporizer, giving clinicians an alternative to allograft for temporarily stabilizing and protecting the wound prior to definitive closure. To further reinforce that positioning, we anticipate results from our PermeaDerm I clinical study later this year. As a reminder, this post-market study assessed PermeaDerm as a clinically comparable, lower-cost alternative to allograft. Currently, 25 hospitals have experience using all three AVITA products. Some already routinely incorporate the entire portfolio into clinical practice, while others continue evaluating where each product fits best within their treatment pathway. That's what we'd anticipate at this point in the adoption of our new products, and it gives us confidence in the opportunity to grow utilization of our full portfolio within our accounts. From the time I took on the CEO role last October, my aim has been simple: to create a company that reliably produces quarter-over-quarter and year-over-year growth by executing commercially with discipline. When I look at the opening six months of 2026, I think that aim has shown up in what we've done. We've posted back-to-back quarters of sequential expansion, seen wider uptake throughout our portfolio, and we keep enhancing the company's financial profile; that momentum leaves us more confident about the direction of the business, so as of today we're revising our outlook to match. To start, our full year 2026 revenue guidance is moving up to a range of $86 million — $89 million, which equals growth of 20%-24% compared with 2025. Next, we're providing fresh guidance for reaching cash flow breakeven and starting to produce cash in the fourth quarter of 2026. Hitting that milestone marks a significant point in AVITA Medical's development. It speaks to both stronger revenue growth and the operating discipline and cash generation that David will cover in greater detail.

David O'Toole executive
#3

Thanks, Cary. Good afternoon — and for those of you in Australia, good morning. In my prepared remarks, I'll walk through the way our solid commercial results are moving through the business, especially when it comes to operating leverage, cash generation, and getting to cash flow breakeven. If we go to the financials on slide four, I'll begin with revenue. Like Cary said, revenue was up roughly 18% versus a year ago, and it rose 13% sequentially from the first quarter, reaching $21.7 million — the first time in our company's history that quarterly revenue has gone past $20 million. Given that sequential increase in the second quarter, along with $41 million of revenue across the first six months of 2026, we're raising our 2026 revenue guidance from $80 million–$85 million to $86 million–$89 million. For this year, that works out to growth from the $71.6 million of revenue in 2025, in a range of about 20%–24%. Now on to gross margin. Gross margin came in at 81.9%, up from 81.2% in the same quarter a year earlier, and it has stayed above 81% year-to-date even as our newer products keep growing. As we've said before, shifts in product mix have a modest effect on the gross margin percentage we report, but Cohealyx and PermeaDerm bring in additional gross profit without a proportional rise in operating expenses. RECELL's gross margin is still strong, at roughly 86%. Growth in RECELL gives reported gross margin a tailwind that offsets the product mix effect as Cohealyx and PermeaDerm account for a bigger share of the business. Moving to operating expenses. They came to $24.6 million, basically flat versus the first quarter and about 6% below the same period in 2025. Importantly, that shows the advantage of the commercial operating structure we put in place in the second quarter of 2025, which can carry continued commercial growth without needing a matching rise in operating expenses. As we look at the remainder of 2026, we keep finding ways to bring operating expenses down further while still supporting our commercial priorities; in this quarter, operating loss and net loss improved to $6.9 million and $7.7 million, respectively, versus $11.1 million and $9.9 million, respectively, in last year's same period. The second quarter's operating and net loss represented substantial improvement over the quarterly losses we posted in the past. Now to cash, which is still among our top priorities. During our first quarter call, we said we expected cash use to get significantly better in the second quarter as seasonal payments returned to normal, collections picked up, and revenue kept scaling. That is precisely what occurred. Net cash use improved to about $3.2 million in the quarter, a major step up from the first quarter and from the cash burn we saw in each quarter last year. We closed the quarter with roughly $11.1 million in cash equivalent, and market securities. When I look at how our numbers are trending, shown in the green boxes on this slide, I see a financial model doing what we expect and consistent with our growing revenue. Like Cary said before, we're also putting out fresh guidance regarding our cash flow outlook. The conviction that we'll hit cash flow breakeven comes from three financial patterns now converging, which you can see on slide five. To start, revenue keeps expanding. We've just posted two straight quarters of solid sequential growth — 9.7% and 13%, in that order — and we've lifted our revenue guidance for the full year. Next, we've held gross margin high, staying above 81%, even as our portfolio grew across several quarters. And third, we've kept operating expenses under strict discipline and improved how efficiently we convert cash. Put simply, running the business costs us less, and we're bringing in cash from operations more quickly. When you combine these patterns, our confidence grows that AVITA is nearing a significant financial inflection point. As the business keeps expanding, we anticipate cash use will drop further in the third quarter, then we reach cash flow breakeven and start producing cash in the fourth quarter of 2026. Now on slide six, our revised outlook strengthens our belief that the balance sheet still fits the company's next growth phase and is funded all the way through this shift to generating cash. We remain comfortably in compliance with our credit facility's terms, which were deliberately designed to carry the business through this period of commercial expansion. As revenue keeps building, the Perceptive debt facility additionally gives us access to a further $10 million tranche when trailing 12-month revenue hits $85 million, which adds financial flexibility as we move toward generating cash. To sum up, we're achieving commercial growth, keeping gross margin strong, holding operating expenses in check, and cutting our cash use substantially. All together, these patterns underpin our confidence in the higher revenue forecast we're sharing today and in our route to cash generation. Today's results also show strong execution throughout the organization. Our commercial, operations, and corporate teams have collaborated exceptionally well to expand the business while preserving financial discipline. I want to thank everyone at AVITA for their dedication and execution over the first half of the year. With that, I'll pass the call back to Cary.

Cary Vance executive
#4

Thanks, David. Ahead of Q&A, I'd like to spend a few minutes discussing RECELL. It sits at the heart of our business, and the momentum we're witnessing is encouraging — both in terms of how doctors apply it and in the reimbursement framework that will support future expansion. Once reimbursement changed across each of the seven Medicare Administrative Contractors, or MACs, physician adoption of RECELL continued to build through Q2. All told, U.S. RECELL volume climbed over 10% versus the previous quarter, surpassing 2,600 units; on top of that, RECELL GO mini is showing up as an additional growth engine. Looking at the slide's right-hand portion, you'll notice that for RECELL GO mini procedures performed during this year up to now, 77% were for wounds of 500 square centimeters or smaller. That matches exactly what we set out to accomplish with the design of RECELL GO mini — extending RECELL's use into smaller burn and trauma wounds. Additionally, the greater volume during Q2 strikes us as an encouraging indicator of physicians' underlying demand for RECELL in circumstances where reimbursement is both stable and predictable. Taking that into account, we are currently in the final stages of transitioning toward new category 1 CPT codes for skin cell suspension autograft, or SCSA, which serves as the procedure term for RECELL. Just a quick note before we go further: beginning on the first of January in 2027, the freshly introduced category 1 CPT code family for SCSA is going to replace the multi-code structure we have in place right now. Under the current arrangement, there are eight codes that separate harvesting, preparation, and application; that will give way to a streamlined family of four codes determined by where the anatomy is located and how large the wound is. Back in July, the Centers for Medicare and Medicaid Services, which we refer to as CMS, put forward nationally published Physician Relative Value Units, or RVUs, for the new SCSA codes as part of the proposed updates to 2027 Medicare payment. Our expectation is that CMS will put the final rule in place sometime later in this year. Starting next January, if this proposal goes through, the way physicians get paid would shift away from the current approach—which relies on regional MAC contractor pricing—and instead follow a nationally published RVU system. That change would give providers more clarity and consistency. Down the road, we think it will streamline how we talk about reimbursement, so our commercial group and our customers can spend less energy wrestling with coding intricacies and more on getting the therapy adopted and caring for patients. Taking a step back to assess the quarter, the figures we're posting are really heartening. Use of RECELL is climbing. Cohealyx—and PermeaDerm after it—are picking up momentum. Each quarter brings more revenue, and by the end of the year we can see a straightforward route to breaking even on cash flow. None of these wins stand alone. These results show that our operations are functioning exactly as planned. Turning to the rest of 2026, we intend to keep applying the same rigor that got us here. We know what we need to focus on. Keep driving greater use of RECELL, keep building momentum behind Cohealyx and PermeaDerm, and keep running the commercial and financial sides of the business with discipline. If we keep delivering on all of that, we're confident AVITA is set up well to deliver long-term shareholder value and to reach more patients with our technologies. We appreciate you being here today and for your ongoing support. Operator, we're ready to begin taking questions now.

Frank Takkinen analyst
#5

Excellent. Thanks for fielding the questions, and congratulations on a very strong quarter. I'd like to ask two things. I'll put both out there now, then get back in line. First, on guidance, could you walk through the main elements driving the increase? I caught the remarks about RECELL GO mini performing well and the recovery, so maybe break down which one mattered more. Second, when you consider reimbursement in 2027, how big a hurdle has the old structure been? In other words, what share of cases, or adoption at the site level, got held up by that old structure, and what do the new economics look like because of it? Thank you.

Cary Vance executive
#6

Thanks, Frank. Appreciate you being with us today. To begin with guidance, it's pretty clear-cut and easy. We're on a path of growth, and at the start of the year when we gave guidance, certain things were known to us and certain things weren't. We provided a rather prudent guidance reflecting the path we expected to be on, and now we're on a steeper path. That's quite evident to us at this point. I believe we have visibility into the remainder of the year. With all our customers, our forecasting has become highly predictable, so we think now is the right moment to lift it to a level we're confident we'll hit. Next, on the reimbursement side, setting the numerical aspect aside, the largest issue a year ago was uncertainty, plus how much time our sales force and our customers spent attempting to figure out whether payment would come, how much payment would come, and at what point. We've taken care of that as a temporary fix, since that's what it was intended to be, via the MACs, gradually, on an account-by-account basis. What this does is streamline the codes, and it also makes things completely consistent across the country. As I mentioned in my prepared remarks, it shifts us away from those clarifying, more intricate conversations with our customers toward concentrating more on the clinical and economic advantages of the products. That will greatly aid the efficiency and effectiveness of our sales team, and I believe it will help our uptake on RECELL, which remains significantly under-penetrated in the market.

Analyst analyst
#7

Hello, Jacqueline here, filling in for Ryan. Thanks for taking my question. I was curious whether the proposed 2027 PFS carries any danger of a transitional gap period while providers shift away from the eight legacy codes toward the four new standardized codes. What does the internal strategy look like for getting out in front of that from an education standpoint?

Cary Vance executive
#8

Certainly. Communication with our teams has already started, and those teams have begun reaching out to our customers. That process is underway now. Although everything will be locked in during late October or early November, that proposed change is probable, so because of that, we're already beginning to teach them how this will shift. A number of the associations we belong to are also informing their members — many burn surgeons — regarding the change too. It amounts to a comprehensive push to ensure everyone has a very clear grasp of it by the moment January 1st arrives.

Analyst analyst
#9

Thanks. You previously said the complete Cohealyx-I data set would arrive at the end of 2026, and encouraging interim results came out in April, showing quicker readiness for skin grafting than the top competing products. Can you verify the schedule for that complete data set remains unchanged? What extra details will help strengthen the case for back approvals and wider use?

Cary Vance executive
#10

Regarding that schedule, we remain on course. The additional information amounts to follow-up data, which will also be included in the submission and the publication.

Analyst analyst
#11

Thank you.

Cary Vance executive
#12

You're welcome. Thank you.

Analyst analyst
#13

Hello there, good afternoon. I appreciate you fielding this, and congratulations on such a strong quarter. Josh couldn't make it, so it's John here instead. What I'd like to ask about briefly concerns how all three of your products are being taken up, and more precisely, what your field sales team members are reporting back. At the doctor level, what sorts of things are they telling you regarding physicians who use all three offerings, and in what way does that shape the way you set prices throughout your portfolio? I did have one short follow-up as well.

Cary Vance executive
#14

So, from a clinical standpoint, I'd say what we hear is quite favorable. In my view, every one of these products can succeed independently, and that's what doctors have conveyed to us regarding how effective they are clinically, plus the financial upside they observe. It remains early in terms of their efforts to work out how having 2 or 3 of what AVITA offers — PermeaDerm, Cohealyx, and RECELL — produces a situation where one plus one gives you five or six through synergies. We're collaborating alongside them to ensure that gets maximized. Extremely encouraging. A number of our strongest accounts are bringing in all 3 of these technologies, and we anticipate that trend will keep moving forward.

Analyst analyst
#15

Alright, that's great. Regarding the pricing for each of the three separate units, I definitely understand that RECELL is accretive when it comes to gross margin. Make no mistake — at the product level, 85%, 86% gross margins are outstanding. Is there any action you can take to further enhance that gross margin so it might offset a portion of the dilution coming from Cohealyx and PermeaDerm?

Cary Vance executive
#16

Certainly. Our operations group keeps searching for efficiencies at the back end of the business. We will keep seeking those out, along with our chance to get the best possible price in the market. That's something we will keep maintaining and attempt to grow moving forward, as we ought to; when it comes to the remaining products, Cohealyx and PermeaDerm, once again, it's still early in the effort to build market penetration. We constantly examine price to confirm we're optimized in that area; we'll keep doing so.

Analyst analyst
#17

Excellent.

Cary Vance executive
#18

Thank you, John.

Operator operator
#19

Thanks. Right now, I see no additional questions. That wraps up the conference call for today. We appreciate everyone joining in. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AVITA Medical, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AVITA Medical, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.